A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
Latest Information Update: 06 Mar 2023
Price :
$35 *
At a glance
- Drugs Imsidolimab (Primary)
- Indications Ichthyosis
- Focus Therapeutic Use
- Acronyms INSPIRE
- Sponsors AnaptysBio
- 19 Sep 2022 Status changed from recruiting to discontinued due to administrative reason
- 22 Dec 2021 This trial has been discontinued in Poland, according to European Clinical Trials Database record.
- 03 May 2021 Status changed from not yet recruiting to recruiting.